在残疾沙特患者中探索药物的药理动力学:系统性审查
Faleh Alqahtani1, Saeed A Al Awadh2,3, Muhammad Fawad Rasool4
1Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Pharmaceuticals (Basel, Switzerland)
|April 26, 2025
概括
与其他种族相比,残疾沙特患者的药物吸收和新陈代谢不同. 了解这些药理动力学变异对于个性化药物剂量和改善患者护理至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 药物新陈代谢 药物新陈代谢
背景情况:
- 残疾包括影响日常生活和社会参与的障碍.
- 残疾人,包括患有,癌症和心血管疾病的人群,可能会表现出药物的药理动力学变化.
- 药物处置的种族差异得到了充分证实,因此需要在不同人群中进行具体的研究.
研究的目的:
- 编制和分析残疾沙特患者药物的药理动力学数据.
- 为了比较沙特残疾患者的药物吸收,分配和处置情况,与其他族群的数据进行比较.
- 确定影响残疾人药物药理动学的因素.
主要方法:
- 系统的在线文献搜索使用主要的科学数据库 (谷歌学者,PubMed,科克兰图书馆,科学直接).
- 包括报告关键药理学参数的研究:曲线下的面积 (AUC),最大血度 (Cmax),清除量 (CL),分布量和半衰期.
- 专注于涉及残疾患者群体的研究.
主要成果:
- 儿科患者表现出与年龄相关的卡巴马西平Cmax下降,这表明药物处置的发育变化.
- 在成年造血干细胞移植患者中,布苏尔方AUC表现出显著的个体间差异.
- 与非癌症患者相比,癌症患者的万科米辛清除值显著更高 (25%).
结论:
- 残疾患者的药物药理动力学变化受到细胞染色体P450酶变异,病理生理学,遗传学和种族的影响.
- 以患者为中心的药物剂量是管理这些药物动力学差异引起的并发症的关键.
- 研究结果支持医疗保健提供者优化残疾患者群体的治疗策略.
相关概念视频
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
41
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
41
01:21Factors Affecting Drug Response: Overview
1.7K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.7K
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
14
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
14
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
27
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
27
01:11Renal Failure: Dose Adjustments
35
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
35
01:12Analysis of Population Pharmacokinetic Data
195
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
195